within Pharmacolibrary.Drugs.ATC.G;

model G03DA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.08,
    Cl             = 9e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0207,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0026666666666666666,
    Tlag           = 1200
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03DA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Progesterone is a natural steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis. It is used as a medication primarily for hormone replacement therapy, treatment of menstrual disorders, and as a component of hormonal contraceptives. Progesterone is approved for use today in various oral, vaginal, and injectable forms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult women after a single oral dose administration of micronized progesterone.</p><h4>References</h4><ol><li><p>Sitruk-Ware, R, et al., &amp; Mauvais-Jarvis, P (1987). Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications--a review. <i>Contraception</i> 36(4) 373–402. DOI:<a href=\"https://doi.org/10.1016/0010-7824(87)90088-6\">10.1016/0010-7824(87)90088-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3327648/\">https://pubmed.ncbi.nlm.nih.gov/3327648</a></p></li><li><p>Stanczyk, FZ (1999). Pharmacokinetics of progesterone administered by the oral and parenteral routes. <i>The Journal of reproductive medicine</i> 44(2 Suppl) 141–147. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11392023/\">https://pubmed.ncbi.nlm.nih.gov/11392023</a></p></li><li><p>Loreti, S, et al., &amp; Mackens, S (2024). Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium. <i>Human reproduction (Oxford, England)</i> 39(2) 403–412. DOI:<a href=\"https://doi.org/10.1093/humrep/dead256\">10.1093/humrep/dead256</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38110714/\">https://pubmed.ncbi.nlm.nih.gov/38110714</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03DA04;
